Gen Digital Inc. Common Stock vs Illumina, Inc. — how do they compare? Gen Digital Inc. Common Stock trades at $22.77 (market cap $13.61B), while Illumina, Inc. trades at $266.99 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 2.9× Gen Digital Inc. Common Stock's market cap, and Gen Digital Inc. Common Stock pays a 2.2% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gen Digital Inc. Common Stock for 0 Days and Illumina, Inc. for 83 Days on average.
| GEN | ILMN | |
|---|---|---|
Market Cap | $13.61B | $39.95B |
Volume | 10,697,883 | 3,169,503 |
Sector | Technology | Health |
52-Week High | $31.41 | $293.69 |
52-Week Low | $17.89 | $91.00 |
Typical Hold Time | 0 Days | 83 Days |
Enterprise Value | $21.25B | $41.31B |
Dividend Yield | 2.2% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Gen Digital provides cybersecurity, online privacy, identity protection, and financial wellness services. Its consumer brands include Norton, Avast, LifeLock, and MoneyLion.
Read more on GEN →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →